Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life
The Journal of Clinical Endocrinology & Metabolism · 16.09.2024 · 109 (10) · 2541-2552
DOI: 10.1210/clinem/dgae181 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 19.03.2024. Verfasst von Vincenzo Marotta und 12 weiteren Autor:innen. Beteiligte Einrichtung: UOC Clinica Endocrinologica e Diabetologica, AOU San Giovanni di Dio e Ruggi d'Aragona, 84131, Salerno, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Iodine Radioisotopes, Phenylurea Compounds, Quinolines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Context
Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). The definition of predictive factors of survival is incomplete.
Objective
To identify pre- and posttreatment survival predictors in a real-life cohort of RR-DTC treated with lenvatinib.
Design
Multicenter, retrospective, cohort study.
Setting
3 Italian thyroid cancer referral centers.
Participants
55 RR-DTC treated with lenvatinib. Main Outcome Measures Progression-free survival (PFS) and overall survival (OS).
Results
Lenvatinib was the first-line kinase-inhibitor in 96.4% of subjects. Median follow-up was 48 months. Median PFS and OS were 26 [95% confidence interval (CI) 19.06-32.93] and 70 months (95% CI 36-111.99), respectively. Pretreatment setting: Eastern Cooperative Oncology Group (ECOG) performance status was independently related to PFS [P < .001; hazard ratio (HR) 18.82; 95% CI 3.65-97.08: score 0-1 as reference] and OS (P = .001; HR 6.20; 95% CI 2.11-18.20; score 0-1 as reference); radioactive iodine (RAI) avidity was independently related to PFS (P = .047; HR 3.74; 95% CI 1.01-13.76; avid disease as reference). Patients with good ECOG status (0-1) and RAI-avid disease obtained objective response in 100% of cases and achieved a median PFS of 45 months without any death upon a median follow-up of 81 months. Posttreatment setting: the best radiological response independently predicted PFS (P = .001; HR 4.6; 95% CI 1.89-11.18; partial/complete response as reference) and OS (P = .013; HR 2.94; 95% CI 1.25-6.89; partial/complete response as reference).
Conclusion
RR-DTC with good performance status and RAI-avid disease obtains the highest clinical benefit from lenvatinib. After treatment initiation, objective response was the only independent survival predictor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UOC Clinica Endocrinologica e Diabetologica, AOU San Giovanni di Dio e Ruggi d'Aragona, 84131, Salerno, Italy.
- Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Salerno, 84084, Salerno, Italy.
- Struttura Complessa Chirurgia Oncologica Della Tiroide, Istituto Nazionale Tumori-Irccs-Fondazione G. Pascale, 80131, Napoli, Italy.
- Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome, 00198, Rome, Italy.
- Struttura Complessa Medicina Nucleare e Terapia Radiometabolica-UOS Terapia Metabolica Sperimentale, Istituto Nazionale Tumori-Irccs-Fondazione G. Pascale, 80131, Napoli, Italy.
- UOC Chirurgia Generale, AOU San Giovanni di Dio e Ruggi d'Aragona, 84131, Salerno, Italy.
ORCID-Profile: Vincenzo Marotta
Zitieren
APA
Marotta, V., Rocco, D., Crocco, A., Deiana, M. G., Martinelli, R., Di Gennaro, F., Valeriani, M., Valvano, L., Caleo, A., Pezzullo, L., Faggiano, A., Vitale, M., & Monti, S. (2024). Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life. The Journal of Clinical Endocrinology & Metabolism, 109(10), 2541-2552. https://doi.org/10.1210/clinem/dgae181
Vancouver
Marotta V, Rocco D, Crocco A, Deiana MG, Martinelli R, Di Gennaro F, et al. Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life. The Journal of Clinical Endocrinology & Metabolism. 2024;109(10):2541-2552. doi:10.1210/clinem/dgae181
BibTeX
@article{Marotta2024,
author = {Marotta, Vincenzo and Rocco, Domenico and Crocco, Anna and Deiana, Maria Grazia and Martinelli, Ruggero and Di Gennaro, Francesca and Valeriani, Mariafelicia and Valvano, Luca and Caleo, Alessia and Pezzullo, Luciano and Faggiano, Antongiulio and Vitale, Mario and Monti, Salvatore},
title = {Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {10},
pages = {2541--2552},
doi = {10.1210/clinem/dgae181}
}
EUVIMED